SYNDIVIA

Executive Summary

Syndivia is a preclinical French biotechnology company developing next-generation antibody-drug conjugates (ADCs) through its proprietary GeminiMab platform. The platform enables site-specific hinge conjugation of toxins to antibodies, allowing precise control over drug-to-antibody ratios (DAR1, DAR2, DAR4) in both single and combination payload formats. This approach aims to overcome limitations of conventional ADCs, such as heterogeneous conjugation and suboptimal therapeutic indices, by ensuring homogeneous, stable conjugates with optimized pharmacokinetics and efficacy. Founded in 2017 and headquartered in Paris, Syndivia is privately held with no disclosed funding or valuation, reflecting its early-stage positioning in the competitive ADC landscape. As a preclinical-stage company, Syndivia's primary focus is advancing its lead candidate(s) through IND-enabling studies and generating compelling preclinical data to support clinical translation. The platform's potential for dual-payload ADCs offers a differentiated strategy to combat tumor heterogeneity and resistance mechanisms. Near-term catalysts include initiation of IND-enabling toxicology studies, presentation of preclinical efficacy data at major oncology conferences, and potential partnership discussions with larger biopharma firms seeking innovative ADC technologies. While the company faces typical early-stage risks, its novel hinge-conjugation platform could capture interest from partners and investors aiming to develop safer and more effective ADCs.

Upcoming Catalysts (preview)

• Q4 2026Lead Candidate IND-Enabling Studies Initiation60% success
• Q3 2026Preclinical Data Presentation at Major Conference80% success
• 2027Strategic Partnership or Licensing Deal40% success